← FDA DRUG APPROVALS

FDA ANDA · ANDA210231

SUCCINYLCHOLINE CHLORIDE

Sponsor: J MOLNER

APPLICATION
ANDA210231
TYPE
ANDA
ORIGINAL APPROVAL
2018-06-04
LATEST ACTION
2020-10-15
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

SUCCINYLCHOLINE CHLORIDEPrescription
SUCCINYLCHOLINE CHLORIDE 20MG/ML · INJECTABLE · INJECTION

Approval history

2020-10-15Labeling · Supplement 4 · standardAP
2020-02-10Labeling · Supplement 2 · standardAP
2020-02-10Labeling · Supplement 3 · standardAP
2018-06-04UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →